Holen Sie sich die Stockscreener-App
19.50
2.58%
0.49
Handel nachbörslich:
19.45
-0.05
-0.26%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt TNDM?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$19.01
Offen:
$19.1
24-Stunden-Volumen:
1.83M
Relative Volume:
0.79
Marktkapitalisierung:
$1.34B
Einnahmen:
$1.03B
Nettoeinkommen (Verlust:
$-94.55M
KGV:
-13.92
EPS:
-1.4012
Netto-Cashflow:
$-3.64M
1W Leistung:
+13.90%
1M Leistung:
+29.22%
6M Leistung:
-1.96%
1J Leistung:
+25.16%
1-Tages-Spanne:
$18.56
$19.66
1-Wochen-Bereich:
$16.34
$19.66
52-Wochen-Spanne:
$9.98
$29.65
Tandem Diabetes Care Inc Stock (TNDM) Company Profile
Firmenname
Tandem Diabetes Care Inc
Sektor
Branche
Telefon
858-366-6900
Adresse
12400 HIGH BLUFF DRIVE, San Diego, CA
Compare TNDM vs ABT, SYK, MDT, BSX, EW
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TNDM
Tandem Diabetes Care Inc
|
19.50 | 1.18B | 1.03B | -94.55M | -3.64M | -1.4012 |
ABT
Abbott Laboratories
|
105.74 | 182.00B | 46.59B | 5.41B | 7.38B | 3.0938 |
SYK
Stryker Corp
|
325.74 | 129.09B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
85.40 | 107.81B | 36.36B | 4.84B | 5.43B | 3.7261 |
BSX
Boston Scientific Corp
|
46.73 | 67.64B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
86.03 | 47.81B | 6.30B | 1.07B | 1.09B | 1.8406 |
Tandem Diabetes Care Inc Stock (TNDM) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-19 | Hochstufung | Truist | Hold → Buy |
| 2026-03-17 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2026-02-23 | Hochstufung | Lake Street | Hold → Buy |
| 2026-02-20 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2026-01-27 | Fortgesetzt | TD Cowen | Buy |
| 2025-12-16 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2025-10-21 | Fortgesetzt | Stifel | Hold |
| 2025-09-08 | Eingeleitet | Oppenheimer | Outperform |
| 2025-08-12 | Hochstufung | Citigroup | Sell → Neutral |
| 2025-08-07 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2025-07-09 | Herabstufung | Citigroup | Neutral → Sell |
| 2025-06-16 | Eingeleitet | Truist | Hold |
| 2025-04-10 | Eingeleitet | Mizuho | Neutral |
| 2025-03-05 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2025-03-04 | Herabstufung | Citigroup | Buy → Neutral |
| 2025-03-03 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2025-02-28 | Herabstufung | Bernstein | Outperform → Mkt Perform |
| 2024-12-02 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2024-11-06 | Eingeleitet | Bernstein | Outperform |
| 2024-10-04 | Eingeleitet | Goldman | Neutral |
| 2024-10-02 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2024-08-22 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2024-08-08 | Eingeleitet | Canaccord Genuity | Buy |
| 2024-05-30 | Eingeleitet | Redburn Atlantic | Buy |
| 2024-05-22 | Hochstufung | Citigroup | Neutral → Buy |
| 2024-04-29 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2024-04-25 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-03-26 | Hochstufung | Stifel | Hold → Buy |
| 2023-08-04 | Herabstufung | Citigroup | Buy → Neutral |
| 2023-05-05 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2023-04-24 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2023-03-29 | Eingeleitet | UBS | Neutral |
| 2023-01-26 | Eingeleitet | Wolfe Research | Peer Perform |
| 2022-11-15 | Hochstufung | Wells Fargo | Underweight → Equal Weight |
| 2022-10-18 | Eingeleitet | Barclays | Overweight |
| 2022-10-12 | Eingeleitet | Jefferies | Buy |
| 2022-08-09 | Herabstufung | Wells Fargo | Overweight → Underweight |
| 2022-03-02 | Fortgesetzt | BofA Securities | Neutral |
| 2022-01-19 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2021-07-21 | Fortgesetzt | Cowen | Outperform |
| 2021-05-25 | Eingeleitet | Barclays | Underweight |
| 2020-12-15 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2020-08-20 | Eingeleitet | Wells Fargo | Overweight |
| 2020-07-31 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-07-06 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-06-18 | Bestätigt | Raymond James | Outperform |
| 2020-04-24 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2020-03-23 | Herabstufung | Guggenheim | Buy → Neutral |
| 2020-03-05 | Eingeleitet | Citigroup | Neutral |
| 2020-02-06 | Eingeleitet | Raymond James | Outperform |
| 2020-02-04 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2019-10-18 | Eingeleitet | Guggenheim | Buy |
| 2019-10-04 | Hochstufung | UBS | Neutral → Buy |
| 2019-05-17 | Bestätigt | BofA/Merrill | Neutral |
| 2019-05-13 | Eingeleitet | SVB Leerink | Outperform |
| 2019-03-08 | Eingeleitet | BMO Capital Markets | Outperform |
| 2019-03-05 | Bestätigt | BofA/Merrill | Neutral |
| 2019-02-27 | Bestätigt | Lake Street | Buy |
| 2018-11-21 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2018-09-26 | Bestätigt | Dougherty & Company | Buy |
| 2018-09-26 | Bestätigt | Piper Jaffray | Overweight |
Alle ansehen
Tandem Diabetes Care Inc Aktie (TNDM) Neueste Nachrichten
TNDM|Tandem Diabetes Care Inc|Price:17.170|Chg%:+0.050 - TradingKey
Tandem Diabetes Care Inc (TNDM) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Tandem Diabetes Care Inc (TNDM) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Tandem Diabetes Care (TNDM) Q1 2024 Earnings ReportResults, Call & Slides - TipRanks
Tandem Diabetes Care (TNDM) Q2 2024 Earnings ReportResults, Call & Slides - TipRanks
TradingKey - TradingKey
Impact of Automated Insulin Delivery on Type 2 Diabetes Measures - AJMC
Tandem Diabetes Care Inc (TNDM) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Insulin Pump Maker Moves To Dismiss Wrongful Death Case On Preemption Grounds - Mealey's
3 Healthcare Stocks with Questionable Fundamentals - Yahoo Finance
Tandem Diabetes Care Inc (TNDM) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
What Tandem Diabetes Care (TNDM)'s CGM Expansion and New Tubeless Rival Mean For Shareholders - Sahm
Understanding the Setup: (TNDM) and Scalable Risk - Stock Traders Daily
Tandem Diabetes Care, Inc. (TNDM) Stock Analysis: Exploring a 60% Potential Upside with Robust Buy Ratings - DirectorsTalk Interviews
Tandem Diabetes Care Inc (TNDM) Shares Surge 6.0% -- What GF Sco - GuruFocus
TNDM6032036 Bond Coupon Profile — Rate & Payments - TradingView
Tandem Diabetes Care, Inc. (TNDM) Stock forecasts - Yahoo Finance UK
Tandem Diabetes Care (0M0F) Q1 2024 Earnings ReportResults, Call & Slides - TipRanks
Can Tandem Diabetes Care (TNDM) Turn Revenue Beats Into Durable Returns On Capital? - webull.com
When Will Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Become Profitable? - 富途牛牛
Tandem Diabetes Care Inc (TNDM) Shares Surge 4.9% -- What GF Sco - GuruFocus
Form 4 Tandem Diabetes Care Inc For: 17 July By Investing.com - Investing.com Nigeria
Tandem Diabetes Care (TNDM) COO logs RSU vesting, 31,741 shares held after tax withholding - Stock Titan
US875372AE4 Bond Profile — Key Metrics - TradingView
Why Did TNDM Stock Jump 5% After Hours Despite Q4 Earnings Miss? - Stocktwits
Unpacking Q1 Earnings: Tandem Diabetes (NASDAQ:TNDM) In The Context Of Other Healthcare Technology Stocks - Yahoo Finance
Mizuho Securities Maintains Tandem Diabetes Care(TNDM.US) With Hold Rating, Cuts Target Price to $20 - Moomoo
TNDM Maintained by Mizuho -- Price Target Lowered to $20.00 - GuruFocus
Analysts Offer Insights on Healthcare Companies: Tandem Diabetes Care (TNDM) and Boston Scientific (BSX) - The Globe and Mail
Tandem Diabetes Care (TNDM) Expands Abbott Compatibility As Undervalued Narrative Faces A Fresh Test - Sahm
Tandem Diabetes Care, Inc. (TNDM) Stock Forecasts - Yahoo Finance
Does Libre 3 Plus Integration Expand Tandem’s Interoperability Edge And Bull Case For TNDM? - Yahoo Finance
No Title Or Subtitle Provided To Check - Finimize
Is Tandem Diabetes Care (TNDM) Undervalued Following Its Abbott Libre 3 Plus Expansion? - Yahoo Finance
Tandem’s Expanded Libre 3 Plus Integration Could Be A Game Changer For Tandem Diabetes Care (TNDM) - Sahm
Tandem Diabetes Care (TNDM) Goldman Sachs 46th Annual Global Healthcare Conference summary - Quartr
Tandem Diabetes Care Inc. (TNDM) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
Citi Maintains Tandem Diabetes Care(TNDM.US) With Hold Rating, Maintains Target Price $17 - Moomoo
Tandem Diabetes Care (TNDM) Stifel 2024 Healthcare Conference Summary - Quartr
Does TNDM Stock Still Deserve a Place in Your Portfolio? - TradingView
Is the Market Underestimating Tandem Diabetes Care, Inc. (TNDM)’s Transition Risks? - Insider Monkey
10 Best Get Rich Quick Stocks to Buy Right Now - Insider Monkey
Tandem Diabetes Care Launches t:slim X2 Insulin Pump Compatibility With Abbott's FreeStyle Libre 3 Plus CGM Sensor - Medical Product Outsourcing
Tandem Diabetes Q1 2026 slides: record revenue, profitability returns - Investing.com
TNDMTandem Diabetes Care Inc Options - Finviz
Tandem Diabetes faces earnings test as pay-as-you-go shift weighs - Investing.com
ETFs Investing in Tandem Diabetes Care, Inc. Stocks - TradingView
TANDEM DIABETES CARE INC (TNDM) Stock Chart - ChartMill
Insulin pump makers Tandem and Insulet post contrasting Q2 results - MSN
Diabetes warning issued over insulin pump error - MSN
Tandem Diabetes Care (TNDM) Expands Compatibility with Abbott's FreeStyle Libre 3 Plus - GuruFocus
Finanzdaten der Tandem Diabetes Care Inc-Aktie (TNDM)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.04%
11.95%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):